---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-267364"
form_type: "8-K"
ticker: "NERV"
cik: "0001598646"
company_name: "Minerva Neurosciences, Inc."
filed_at: "2021-09-08T23:59:59+00:00"
generated_at: "2026-06-29T05:12:25.510408+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Minerva Neurosciences appoints Dr. Kuchibhatla as SVP Head of R&D; Dr. Saoud to advisory role

## Summary
- Dr. Jay Saoud resigns as SVP Head of R&D effective Sept 15, 2021; transitions to consultant through June 2022.
- Dr. Ramana Kuchibhatla appointed as Senior VP & Head of R&D effective Sept 16, 2021, reporting to CEO.
- Saoud will continue supporting preparation and submission of NDA for roluperidone (negative symptoms of schizophrenia).
- Consulting fee: $412.50/hr first 20 hrs/wk, $500/hr beyond; equity awards accelerate upon completion or early termination.
- Kuchibhatla has over 35 years drug development experience from PRA Health Sciences, Melior, Targacept, GSK.

## SEC filing metadata
- accession: 0001193125-21-267364
- form_type: 8-K
- ticker: NERV
- cik: 0001598646
- company_name: Minerva Neurosciences, Inc.
- filed_at: 2021-09-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1598646/000119312521267364/0001193125-21-267364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1598646/000119312521267364/d196078d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-267364
- JSON: https://secwatch.observer/filing/0001193125-21-267364.json
- Plain text: https://secwatch.observer/filing/0001193125-21-267364.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.